<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936324</url>
  </required_header>
  <id_info>
    <org_study_id>DRM01B-ACN01</org_study_id>
    <nct_id>NCT01936324</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel</brief_title>
  <official_title>A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2a study.&#xD;
&#xD;
      The purpose of Phase 1 was to evaluate the safety and tolerability of DRM01B Topical Gel in 6&#xD;
      healthy volunteers.&#xD;
&#xD;
      The purpose of Phase 2a was to assess the safety, tolerability and preliminary efficacy of&#xD;
      DRM01B Topical Gel compared to vehicle in subjects with acne vulgaris on the face.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a&#xD;
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions&#xD;
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion&#xD;
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)&#xD;
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion&#xD;
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olumacostat Glasaretil Gel, 7.5%</intervention_name>
    <description>Gel containing Olumacostat Glasaretil</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2a</arm_group_label>
    <other_name>DRM01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olumacostat Glasaretil Gel, Vehicle</intervention_name>
    <description>Vehicle (placebo) gel</description>
    <arm_group_label>Phase 2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1 Inclusion Criteria&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Willing to comply with the requirements of the protocol&#xD;
&#xD;
          3. Males or non-pregnant, non-lactating females&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Was in good health and free from any clinically significant disease, as determined by&#xD;
             the investigator&#xD;
&#xD;
          6. If female and of childbearing potential, was willing to use an accepted method of&#xD;
             birth control during study participation and for 30 days after the last application of&#xD;
             study drug. Females were considered to be of childbearing potential unless they had&#xD;
             been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), had&#xD;
             been diagnosed as infertile, had a same-sex partner or vasectomized male partner, were&#xD;
             postmenopausal for at least 1 year, or were abstinent. Acceptable methods of birth&#xD;
             control were defined as: abstinence, oral contraceptives, contraceptive&#xD;
             patches/implants; Depo-Provera®, double barrier methods (e.g., condom and spermicide)&#xD;
             or an intrauterine device (IUD). The birth control method must have been&#xD;
             stable/unchanged for 30 days prior to baseline.&#xD;
&#xD;
          7. If male, was vasectomized or agreed to use an accepted method of birth control with&#xD;
             female partner during study participation and for 30 days after the last application&#xD;
             of study drug.&#xD;
&#xD;
        Phase 1 Exclusion Criteria&#xD;
&#xD;
          1. Females who were pregnant, planning to become pregnant during the course of the study,&#xD;
             or were breast-feeding&#xD;
&#xD;
          2. Had a known hypersensitivity to DRM01B or its excipients&#xD;
&#xD;
          3. Had any skin condition that may have interfered with the safety evaluations during the&#xD;
             study&#xD;
&#xD;
          4. Had a clinical chemistry or hematology laboratory value at screening that was&#xD;
             considered clinically significant, in the opinion of the investigator&#xD;
&#xD;
          5. Participated in an investigational drug study within 30 days prior to screening&#xD;
&#xD;
          6. Were considered a poor medical risk because of other systemic diseases or active&#xD;
             uncontrolled infections, in the opinion of the investigator. Any other condition&#xD;
             which, in the judgment of the investigator, would put the subject at unacceptable risk&#xD;
             for participation in the study.&#xD;
&#xD;
        Phase 2a Inclusion Criteria&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Willing to comply with the requirements of the protocol&#xD;
&#xD;
          3. Male or non-pregnant, non-lactating females&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. If female and of childbearing potential, was willing to use an accepted method of&#xD;
             birth control during study participation and for 30 days after the last study drug&#xD;
             application. Females were considered to be of childbearing potential unless surgically&#xD;
             sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), had been diagnosed&#xD;
             as infertile, had same sex partner or vasectomized male partner, or were&#xD;
             postmenopausal for at least 1 year. Acceptable methods of birth control were defined&#xD;
             as: abstinence, oral contraceptives, contraceptive patches/implants; Depo-Provera®,&#xD;
             double barrier methods (e.g., condom and spermicide) or an IUD. The birth control&#xD;
             method must have been stable/unchanged for 12 weeks prior to baseline and must have&#xD;
             remained unchanged during study participation.&#xD;
&#xD;
          6. If male, was vasectomized or agreed to use an accepted method of birth control with&#xD;
             female partner during study participation and for 30 days after the last study drug&#xD;
             application.&#xD;
&#xD;
          7. Subjects were in good health and free from any disease that, in the opinion of the&#xD;
             investigator, would have put the subject at risk during participation in the study.&#xD;
&#xD;
          8. Clinical diagnosis of facial acne vulgaris defined as:&#xD;
&#xD;
               -  At least 20 inflammatory lesions&#xD;
&#xD;
               -  At least 20 noninflammatory lesions&#xD;
&#xD;
               -  IGA of 3 or greater&#xD;
&#xD;
          9. Willing to refrain from using any treatments, other than the investigational product,&#xD;
             including antibiotics, for acne present on the face. Topical acne treatments that did&#xD;
             not have significant or measurable systemic absorption (e.g., benzoyl peroxide,&#xD;
             salicylic acid) were allowed for treatment of acne of the back, shoulders, and chest&#xD;
             only.&#xD;
&#xD;
        Phase 2a Exclusion Criteria&#xD;
&#xD;
          1. Females who were pregnant, planning to become pregnant during the course of the study,&#xD;
             or breast-feeding&#xD;
&#xD;
          2. Had a known hypersensitivity to DRM01B or its excipients&#xD;
&#xD;
          3. Had any skin condition that may have interfered with evaluation of safety or acne&#xD;
             vulgaris (e.g., rosacea; seborrheic dermatitis; perioral dermatitis;&#xD;
             corticosteroid-induced acne or folliculitis)&#xD;
&#xD;
          4. Had excessive facial hair that would have interfered with diagnosis or assessment of&#xD;
             acne vulgaris&#xD;
&#xD;
          5. Had excessive sun exposure, in the opinion of the investigator, or use of tanning&#xD;
             booths&#xD;
&#xD;
          6. Had active cystic acne or acne conglobata, acne fulminans, and secondary acne&#xD;
&#xD;
          7. Had 2 or more active nodular lesions&#xD;
&#xD;
          8. Had a clinical chemistry or hematology laboratory value at screening that was&#xD;
             considered clinically significant, in the opinion of the investigator&#xD;
&#xD;
          9. Participated in an investigational drug study within 30 days prior to screening&#xD;
&#xD;
         10. Subjects who were a poor medical risk because of other systemic diseases or active&#xD;
             uncontrolled infections, in the opinion of the investigator&#xD;
&#xD;
         11. Any other condition that, in the judgment of the investigator, would have put the&#xD;
             subject at unacceptable risk during participation in the study&#xD;
&#xD;
         12. Treatment with over-the-counter (OTC) topical medications for the treatment of acne&#xD;
             vulgaris including benzoyl peroxide, topical anti-inflammatory medications,&#xD;
             corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to baseline&#xD;
&#xD;
         13. Treatment with systemic corticosteroids within 4 weeks prior to baseline (Note: use of&#xD;
             intranasal and inhaled corticosteroids was allowed for seasonal allergies and asthma)&#xD;
&#xD;
         14. Treatment with systemic antibiotics, systemic anti-acne drugs, or systemic&#xD;
             anti-inflammatory drugs within 4 weeks prior to baseline&#xD;
&#xD;
         15. Prescription topical retinoid use on the face within 4 weeks of baseline (e.g.,&#xD;
             tretinoin, tazarotene, adapalene).&#xD;
&#xD;
         16. Treatment with a new hormonal therapy or dose change to an existing hormonal therapy&#xD;
             within 12 weeks prior to baseline. The dose and frequency of use of any hormonal&#xD;
             therapy started more than 12 weeks prior to baseline must have remained unchanged&#xD;
             throughout the study. Hormonal therapies included, but were not limited to, estrogenic&#xD;
             and progestational agents, such as birth control pills.&#xD;
&#xD;
         17. Prior use of androgen receptor blockers (such as spironolactone or flutamide)&#xD;
&#xD;
         18. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A&#xD;
             supplements greater than 10,000 units/day within 6 months of baseline&#xD;
&#xD;
         19. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8&#xD;
             weeks or during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Drew</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guildford Dermatology Specialist Inc</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cosmetic &amp; Laser Surgery</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <results_first_submitted>January 31, 2019</results_first_submitted>
  <results_first_submitted_qc>January 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 1</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
        </group>
        <group group_id="P2">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 1</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
        </group>
        <group group_id="B2">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="11.3"/>
                    <measurement group_id="B2" value="23.9" spread="6.1"/>
                    <measurement group_id="B3" value="26.5" spread="9.0"/>
                    <measurement group_id="B4" value="26.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Fitzpatrick Skin Type is a scale to numerically classify skin color, defined by the response to ultraviolet (UV) light with the following categories:&#xD;
Type I Burns easily, rarely tans Type II Burns easily, tans minimally Type III Burns moderately, tans gradually Type IV Burns minimally, tans well Type V Rarely burns, tans profusely Type VI Never burns, deeply pigmented</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a</title>
        <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a</title>
          <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a</description>
          <population>Intent-to-Treat</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.865" spread="1.107"/>
                    <measurement group_id="O2" value="-14.296" spread="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, baseline lesion count, and center.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a</title>
        <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a</title>
          <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a</description>
          <population>Intent-to-Treat</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.131" spread="1.902"/>
                    <measurement group_id="O2" value="-12.357" spread="1.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, baseline lesion count, and center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a</title>
        <description>Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a&#xD;
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions&#xD;
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion&#xD;
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)&#xD;
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion&#xD;
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a</title>
          <description>Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a&#xD;
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions&#xD;
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion&#xD;
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)&#xD;
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion&#xD;
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
          <population>Intent-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 12</time_frame>
      <desc>The Total Participants at risk are based on the Safety Population defined as Participants who were randomized and received at least one confirmed dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 1</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
        </group>
        <group group_id="E2">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture Right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

